candesartan has been researched along with Body Weight in 47 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both candesartan and a low dose of hydrochlorothiazide are effective and well-tolerated antihypertensive agents in isolated systolic hypertension with additive effects in combination." | 9.10 | Candesartan and hydrochlorothiazide in isolated systolic hypertension. ( Arnolda, LF; Molloy, D; Upton, J; Wing, LM, 2003) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 7.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 7.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "These data demonstrate that the urinary excretion of angiotensinogen is markedly augmented in ANG II-dependent malignant hypertension." | 7.76 | Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. ( Kobori, H; Milani, CJ; Mitchell, KD; Mullins, JJ, 2010) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 7.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| "To clarify the mechanism of the effects of angiotensin II receptor type 1 antagonist, candesartan, upon cardiac adiponectin in the combination of myocarditis with obesity, we examined obese KKAy mice with acute viral myocarditis treated by candesartan and investigated cardiac adiponectin regulation." | 7.74 | Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. ( Chen, R; Iwai, K; Kanda, T; Matsumoto, M; Morimoto, S; Nakahashi, T; Sumino, H; Takahashi, T; Yu, F, 2008) |
| "These results indicate that easily determined characteristics such as ethnicity, gender, body weight, as well as pretreatment levels of BP and PRA predict a substantial fraction of the BP response to candesartan and support the notion that characteristics associated with a poor response to diuretic therapy are associated with better responses to an angiotensin receptor blocker (ARB)." | 7.74 | Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. ( Baranco-Pryor, E; Boerwinkle, E; Canzanello, VJ; Chapman, AB; Rahbari-Oskoui, F; Schwartz, GL; Turner, ST, 2008) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 7.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 7.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| "The aim of this study is to compare the effects of candesartan and olmesartan on insulin sensitivity-related parameters, before and after antihypertensive therapy." | 5.14 | Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2010) |
| "Both candesartan and a low dose of hydrochlorothiazide are effective and well-tolerated antihypertensive agents in isolated systolic hypertension with additive effects in combination." | 5.10 | Candesartan and hydrochlorothiazide in isolated systolic hypertension. ( Arnolda, LF; Molloy, D; Upton, J; Wing, LM, 2003) |
| " CD-fed SHR were simultaneously treated with either telmisartan (TEL; 8 mg/kg(body weight)· d) or candesartan (CAND; 10 mg/kg(body weight)· d) for 3 months because TEL, but not CAND, has been demonstrated to be a strong activator of PPARγ." | 3.78 | Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation. ( Heidbreder, M; Jöhren, O; Landolt, J; Müller-Fielitz, H; Raasch, W; Vogt, FM; Werth, S, 2012) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 3.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 3.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "These data demonstrate that the urinary excretion of angiotensinogen is markedly augmented in ANG II-dependent malignant hypertension." | 3.76 | Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. ( Kobori, H; Milani, CJ; Mitchell, KD; Mullins, JJ, 2010) |
| " After 16 weeks, they were randomized into 4 groups (n = 10 each) with comparable proteinuria: (1) control group sacrificed immediately for baseline data, and groups gavaged daily for 8 weeks with (2) placebo, (3) perindopril (1 mg/kg/day), or (4) candesartan (10 mg/kg/day)." | 3.75 | Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system. ( Amann, K; Boor, P; Heidland, A; Lill, M; Sebeková, K, 2009) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 3.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| "Both TAK-536 and candesartan suppressed the increase in plasma glucose level in the OGTT without significant change in insulin concentration and improved insulin sensitivity." | 3.74 | TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. ( Chen, R; Horiuchi, M; Imura, Y; Iwai, M, 2007) |
| "To clarify the mechanism of the effects of angiotensin II receptor type 1 antagonist, candesartan, upon cardiac adiponectin in the combination of myocarditis with obesity, we examined obese KKAy mice with acute viral myocarditis treated by candesartan and investigated cardiac adiponectin regulation." | 3.74 | Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. ( Chen, R; Iwai, K; Kanda, T; Matsumoto, M; Morimoto, S; Nakahashi, T; Sumino, H; Takahashi, T; Yu, F, 2008) |
| "These results indicate that easily determined characteristics such as ethnicity, gender, body weight, as well as pretreatment levels of BP and PRA predict a substantial fraction of the BP response to candesartan and support the notion that characteristics associated with a poor response to diuretic therapy are associated with better responses to an angiotensin receptor blocker (ARB)." | 3.74 | Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. ( Baranco-Pryor, E; Boerwinkle, E; Canzanello, VJ; Chapman, AB; Rahbari-Oskoui, F; Schwartz, GL; Turner, ST, 2008) |
| "We recently demonstrated that both lisinopril and candesartan, an angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker, respectively, attenuate pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori (WBN/Kob) rats." | 3.73 | Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. ( Ando, T; Itoh, M; Joh, T; Kuno, A; Masuda, K; Nakamura, S; Nomura, T; Ogawa, K; Ohara, H; Okamoto, T; Shirai, T; Tang, M; Yamada, T, 2005) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 3.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| " Cardiomyopathic hearts showed significant increases in % fibrosis, % apoptosis, and myocyte diameter/body weight ratio; candesartan treatment reversed these changes." | 3.73 | Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. ( Aizawa, Y; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, S; Prakash, P; Soga, M; Tachikawa, H; Veeraveedu, P; Watanabe, K, 2006) |
| " Chronic administration of haloperidol significantly increased oxidative stress and neuro-inflammation in the striatum region of the rat's brain." | 1.42 | Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. ( Bansal, PK; Bisht, R; Prakash, A; Thakur, KS, 2015) |
| "Type 1 diabetes was induced in rats by intraperitoneally injecting spontaneously hypertensive rats with streptozotocin." | 1.35 | Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats. ( Hayashi, K; Iigaya, K; Itoh, H; Kamayachi, T; Kumagai, H; Onami, T; Osaka, M; Sakata, K; Saruta, T; Takimoto, C, 2008) |
| "Also, body weight was measured two times, at initial time (before STZ injection) and terminal (at the last day in the experiment)." | 1.33 | Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats. ( Awad, AS, 2006) |
| "Candesartan treatment prevented the hypertension (87 +/- 3 mmHg) and led to increased plasma Ang II concentrations (441 +/- 27 fmol/ml), but prevented increases in kidney (120 +/- 15 fmol/g) and renal interstitial fluid (2." | 1.32 | Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension. ( Navar, LG; Nishiyama, A; Seth, DM, 2003) |
| " Estrogen has been shown to downregulate angiotensin type 1 (AT1) receptor expression and to increase the bioavailability of endothelium-derived NO, which decreases AT1 receptor expression." | 1.32 | Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. ( Harrison-Bernard, LM; Raij, L; Schulman, IH, 2003) |
| "Treatment with candesartan, but not the combination of hydralazine and hydrochlorothiazide, significantly increased the expression of Cx37 and Cx40, although blood pressure decreased similarly." | 1.32 | Angiotensin II receptor blockade corrects altered expression of gap junctions in vascular endothelial cells from hypertensive rats. ( Abe, I; Fujii, K; Goto, K; Iida, M; Kansui, Y; Nakamura, K; Oniki, H; Shibata, Y, 2004) |
| "Focal cerebral ischemia, induced by middle cerebral artery occlusion/reperfusion (MCAO), was conducted at 4 wk after STZ injection." | 1.32 | Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. ( Granger, DN; Ishikawa, M; Kusaka, G; Kusaka, I; Nanda, A; Tang, J; Zhang, JH; Zhou, C, 2004) |
| "Treatment with candesartan attenuated all of these changes and prevented significant albuminuria." | 1.32 | Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. ( Fan, Q; Gohda, T; Gu, L; Horikoshi, S; Kobayashi, M; Liao, J; Suzuki, Y; Tomino, Y; Wang, LN; Yamashita, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.26) | 18.2507 |
| 2000's | 36 (76.60) | 29.6817 |
| 2010's | 9 (19.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thakur, KS | 1 |
| Prakash, A | 1 |
| Bisht, R | 1 |
| Bansal, PK | 1 |
| Susic, D | 2 |
| Krousel-Wood, M | 1 |
| Zhou, X | 2 |
| Frohlich, ED | 2 |
| Sebeková, K | 1 |
| Lill, M | 1 |
| Boor, P | 1 |
| Heidland, A | 1 |
| Amann, K | 1 |
| Makita, S | 1 |
| Abiko, A | 1 |
| Naganuma, Y | 1 |
| Moriai, Y | 1 |
| Nakamura, M | 1 |
| Takimoto, C | 1 |
| Kumagai, H | 1 |
| Osaka, M | 1 |
| Sakata, K | 1 |
| Onami, T | 1 |
| Kamayachi, T | 1 |
| Iigaya, K | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Itoh, H | 1 |
| Zhou, MS | 1 |
| Schulman, IH | 2 |
| Raij, L | 2 |
| Kozak, A | 1 |
| Ergul, A | 1 |
| El-Remessy, AB | 1 |
| Johnson, MH | 1 |
| Machado, LS | 1 |
| Elewa, HF | 1 |
| Abdelsaid, M | 1 |
| Wiley, DC | 1 |
| Fagan, SC | 1 |
| Yang, R | 1 |
| Walther, T | 1 |
| Gembardt, F | 1 |
| Smolders, I | 1 |
| Vanderheyden, P | 1 |
| Albiston, AL | 1 |
| Chai, SY | 1 |
| Dupont, AG | 1 |
| Pelisch, N | 1 |
| Hosomi, N | 1 |
| Ueno, M | 1 |
| Masugata, H | 1 |
| Murao, K | 1 |
| Hitomi, H | 1 |
| Nakano, D | 1 |
| Kobori, H | 2 |
| Nishiyama, A | 2 |
| Kohno, M | 1 |
| Yamaguchi, K | 1 |
| Tsutsumi, E | 1 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Salvadeo, SA | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Mereu, R | 1 |
| Palumbo, I | 1 |
| Fogari, E | 1 |
| D'Angelo, A | 1 |
| Cicero, AF | 1 |
| Milani, CJ | 1 |
| Mullins, JJ | 1 |
| Mitchell, KD | 1 |
| Ishimitsu, T | 1 |
| Honda, T | 2 |
| Ohno, E | 1 |
| Furukata, S | 1 |
| Sudo, Y | 1 |
| Nakano, N | 1 |
| Takahashi, T | 2 |
| Ono, H | 1 |
| Matsuoka, H | 2 |
| Müller-Fielitz, H | 1 |
| Landolt, J | 1 |
| Heidbreder, M | 1 |
| Werth, S | 1 |
| Vogt, FM | 1 |
| Jöhren, O | 1 |
| Raasch, W | 1 |
| Sueta, D | 1 |
| Nakamura, T | 1 |
| Dong, YF | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Yamamoto, E | 1 |
| Toyama, K | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Padi, SS | 1 |
| Chopra, K | 1 |
| Chabrashvili, T | 1 |
| Kitiyakara, C | 1 |
| Blau, J | 1 |
| Karber, A | 1 |
| Aslam, S | 1 |
| Welch, WJ | 1 |
| Wilcox, CS | 1 |
| Yamada, T | 2 |
| Kuno, A | 2 |
| Masuda, K | 2 |
| Ogawa, K | 2 |
| Sogawa, M | 1 |
| Nakamura, S | 2 |
| Ando, T | 2 |
| Sano, H | 1 |
| Nakazawa, T | 1 |
| Ohara, H | 2 |
| Nomura, T | 2 |
| Joh, T | 2 |
| Itoh, M | 2 |
| Hayashi, T | 2 |
| Sohmiya, K | 1 |
| Ukimura, A | 1 |
| Endoh, S | 1 |
| Mori, T | 2 |
| Shimomura, H | 1 |
| Okabe, M | 2 |
| Terasaki, F | 1 |
| Kitaura, Y | 2 |
| Seth, DM | 1 |
| Navar, LG | 1 |
| Yao, K | 1 |
| Sato, H | 1 |
| Ina, Y | 1 |
| Suzuki, K | 1 |
| Ohno, T | 1 |
| Shirakura, S | 1 |
| Wing, LM | 1 |
| Arnolda, LF | 1 |
| Upton, J | 1 |
| Molloy, D | 1 |
| Harrison-Bernard, LM | 1 |
| Sata, N | 1 |
| Tanaka, Y | 1 |
| Suzuki, S | 1 |
| Kamimura, R | 1 |
| Mifune, H | 1 |
| Nakamura, K | 2 |
| Miyahara, K | 1 |
| Arima, T | 1 |
| Kansui, Y | 1 |
| Fujii, K | 1 |
| Goto, K | 1 |
| Oniki, H | 1 |
| Abe, I | 3 |
| Shibata, Y | 1 |
| Iida, M | 2 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 1 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Kusaka, I | 1 |
| Kusaka, G | 1 |
| Zhou, C | 1 |
| Ishikawa, M | 1 |
| Nanda, A | 1 |
| Granger, DN | 1 |
| Zhang, JH | 1 |
| Tang, J | 1 |
| Fan, Q | 1 |
| Liao, J | 1 |
| Kobayashi, M | 1 |
| Yamashita, M | 1 |
| Gu, L | 1 |
| Gohda, T | 1 |
| Suzuki, Y | 1 |
| Wang, LN | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
| Tang, M | 1 |
| Okamoto, T | 1 |
| Shirai, T | 1 |
| Okuda, N | 1 |
| Inamoto, S | 1 |
| Mieno, S | 1 |
| Horimoto, H | 1 |
| Takahashi, M | 1 |
| Tanonaka, K | 1 |
| Yoshida, H | 1 |
| Koshimizu, M | 1 |
| Oikawa, R | 1 |
| Daicho, T | 1 |
| Takeo, S | 1 |
| Lu, Q | 1 |
| Zhu, YZ | 1 |
| Wong, PT | 1 |
| Soga, M | 1 |
| Kamal, FA | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Palaniyandi, S | 1 |
| Prakash, P | 1 |
| Veeraveedu, P | 1 |
| Mito, S | 1 |
| Kunisaki, M | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Awad, AS | 1 |
| Ozacmak, VH | 1 |
| Sayan, H | 1 |
| Cetin, A | 1 |
| Akyildiz-Igdem, A | 1 |
| Iwai, M | 1 |
| Chen, R | 2 |
| Imura, Y | 1 |
| Horiuchi, M | 1 |
| Tsutsui, H | 1 |
| Matsushima, S | 1 |
| Kinugawa, S | 1 |
| Ide, T | 1 |
| Inoue, N | 1 |
| Ohta, Y | 1 |
| Yokota, T | 1 |
| Hamaguchi, S | 1 |
| Sunagawa, K | 1 |
| Yu, F | 1 |
| Sumino, H | 1 |
| Morimoto, S | 1 |
| Nakahashi, T | 1 |
| Iwai, K | 1 |
| Matsumoto, M | 1 |
| Kanda, T | 1 |
| Blumenfeld, JD | 1 |
| Canzanello, VJ | 1 |
| Baranco-Pryor, E | 1 |
| Rahbari-Oskoui, F | 1 |
| Schwartz, GL | 1 |
| Boerwinkle, E | 1 |
| Turner, ST | 1 |
| Chapman, AB | 1 |
| Bennai, F | 1 |
| Morsing, P | 1 |
| Paliege, A | 1 |
| Ketteler, M | 1 |
| Mayer, B | 1 |
| Tapp, R | 1 |
| Bachmann, S | 1 |
| Matsumura, K | 3 |
| Averill, DB | 1 |
| Ferrario, CM | 1 |
| Lin, Y | 2 |
| Tsuchihashi, T | 2 |
| Kagiyama, S | 1 |
| Pollock, DM | 1 |
| Derebail, VK | 1 |
| Yamamoto, T | 1 |
| Pollock, JS | 1 |
| Kobayashi, N | 1 |
| Nakano, S | 1 |
| Mita, S | 1 |
| Kobayashi, T | 1 |
| Tsubokou, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for candesartan and Body Weight
| Article | Year |
|---|---|
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles | 2008 |
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compou | 2010 |
Candesartan and hydrochlorothiazide in isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Australia; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressu | 2003 |
44 other studies available for candesartan and Body Weight
| Article | Year |
|---|---|
Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Body Weight; Grooming; Haloperidol; Hand | 2015 |
Partial adherence to antihypertensive therapy fails to achieve full cardiovascular benefits in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Weight; Disease Models, A | 2008 |
Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2009 |
Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2008 |
Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzi | 2009 |
Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Body We | 2009 |
Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Benzimidazoles; Biphenyl Compoun | 2009 |
Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Benzimidazoles; Bip | 2010 |
Systemic candesartan reduces brain angiotensin II via downregulation of brain renin-angiotensin system.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2010 |
The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antipsychotic Agents; Benzimidazol | 2010 |
Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compound | 2010 |
Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ injuries in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; D | 2010 |
Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Co | 2012 |
Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bl | 2012 |
Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 2002 |
Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2003 |
Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2003 |
Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 2003 |
Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2003 |
Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2003 |
Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2003 |
Effectiveness of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker on atrial natriuretic peptide.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2003 |
Angiotensin II receptor blockade corrects altered expression of gap junctions in vascular endothelial cells from hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Antihypertensive | 2004 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2004 |
Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Body Weight; Di | 2004 |
Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats.
Topics: Actins; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazol | 2005 |
Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; C | 2005 |
Effects of angiotensin I-converting enzyme inhibitor and angiotensin II type 1 receptor blocker on the right ventricular sarcoglycans and dystrophin after left coronary artery ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2005 |
Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; B | 2005 |
Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis | 2006 |
Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2006 |
AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2007 |
TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphen | 2007 |
Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Blo | 2007 |
Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin.
Topics: Adiponectin; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; Cardiovirus Infections; Encep | 2008 |
Plasma renin activity for predicting antihypertensive drug efficacy.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biomarkers | 2008 |
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Bi | 2008 |
Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Blood Pre | 1999 |
Role of AT1 receptors in area postrema on baroreceptor reflex in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Baroreflex; Benzimidazoles; Biphenyl Compounds; Blood Pre | 1999 |
The influence of chronic antihypertensive treatment on the central pressor response in SHR.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2001 |
Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrasentan; Benzimidazoles; Biphenyl Comp | 2000 |
Chronic central infusion of orexin-A increases arterial pressure in rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; B | 2002 |
Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
Topics: Amides; Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; Hemodynamics; Hype | 2002 |